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Infections caused by Pseudomonas aeruginosa often are hard to treat; inappropriate
chemotherapy readily selects multidrug-resistant P. aeruginosa. This organism can be
exposed to a wide range of concentrations of antimicrobials during treatment; learning
more about the responses of P. aeruginosa to antimicrobials is therefore important. We
review here responses of the bacterium P. aeruginosa upon exposure to antimicrobials at
levels below the inhibitory concentration. Carbapenems (e.g., imipenem) have been shown
to induce the formation of thicker and more robust bioﬁlms, while ﬂuoroquinolones (e.g.,
ciproﬂoxacin) and aminoglycosides (e.g., tobramycin) have been shown to induce bioﬁlm
formation. Ciproﬂoxacin also has been demonstrated to enhance the frequency ofmutation
to carbapenem resistance. Conversely, although macrolides (e.g., azithromycin) typically
are not effective against P. aeruginosa because of the pseudomonal outer-membrane
impermeability and efﬂux, macrolides do lead to a reduction in virulence factor production.
Similarly, tetracycline is not very effective against this organism, but is known to induce the
type-III secretion system and consequently enhance cytotoxicity of P. aeruginosa in vivo.
Of special note are the effects of antibacterials and disinfectants on pseudomonal efﬂux
systems. Sub-inhibitory concentrations of protein synthesis inhibitors (aminoglycosides,
tetracycline, chloramphenicol, etc.) induce the MexXY multidrug efﬂux system. This
response is known to bemediated by interferencewith the translation of the leader peptide
PA5471.1, with consequent effects on expression of the PA5471 gene product. Additionally,
induction of the MexCD-OprJ multidrug efﬂux system is observed upon exposure to sub-
inhibitory concentrations of disinfectants such as chlorhexidine and benzalkonium. This
response is known to be dependent upon the AlgU stress response factor. Altogether,
these biological responses of P. aeruginosa provide useful clues for the improvement and
optimization of chemotherapy in order to appropriately treat pseudomonal infections while
minimizing the emergence of resistance.
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INTRODUCTION
Pseudomonas aeruginosa, a motile, non-fermenting Gram-
negative bacterium, is an opportunistic pathogen implicated in
respiratory infections, urinary tract infections, gastrointestinal
infections, keratitis, otitis media, and bacteremia in patients with
compromised host defenses [e.g., cancer, burn, HIV, and cystic
ﬁbrosis (CF)]. These infections often result in signiﬁcant morbid-
ity and mortality. In the 21st century, when the life expectancy
of highly susceptible immunocompromised groups has been
extended in most countries, P. aeruginosa plays an increasingly
prominent role in hospital infections.
This organism is a ubiquitous and metabolically versatile
microbe that ﬂourishes in many environments. The bacterium
grows under both aerobic and anaerobic conditions, and possesses
numerous virulence factors that contribute to its pathogenesis
(Schurek et al., 2012). Moreover P. aeruginosa possesses an intrin-
sic resistance to many antimicrobials because of the bacterium’s
outer-membrane barrier, the presence of multidrug efﬂux trans-
porters, and endogenous antimicrobial inactivation (Poole, 2011).
Although anti-pseudomonas agents (e.g., carbapenems) have been
discovered and developed, P. aeruginosa readily acquires resistance
to individual agents via chromosomal mutations and lateral gene
transfer (Poole, 2011).
Pseudomonas aeruginosa possesses multifactorial mechanisms
of responses and resistance to antimicrobials. While antimicro-
bials were originally developed and used to kill bacteria, recent
work reveals that the biological functions of antibiotics are not
limited to bactericidal (killing) or bacteriostatic (growth inhibi-
tion) effects (Linares et al., 2006; Aminov, 2013). The most likely
function of antibiotics in natural ecosystems is in intercellular
“signaling,” with speciﬁc consequences on the collective behavior
of the bacterial population (Linares et al., 2006; Aminov, 2013).
Improved genetic tools and cutting-edge technologies (e.g., DNA
microarrays) have revolutionized our understanding of microbial
physiology (Wecke and Mascher, 2011). Here, we summarize and
discuss how P. aeruginosa responds to various antimicrobials and
survives against its competitors.
RESPONSES TO β-LACTAMS
β-lactams bind to cell wall transpeptidases [penicillin binding pro-
teins (PBPs)], blocking an important step inpeptidoglycanbiosyn-
thesis (Poole, 2004). Penicillins (e.g., ticarcillin, piperacillin),
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cephalosporins (e.g., ceftazidime, cefepime), monobactams (e.g.,
aztreonam), and carbapenems (e.g., imipenem, meropenem, and
doripenem) are commonly used to treat pseudomonal infec-
tions. P. aeruginosa is intrinsically resistant to most β-lactams
due to the interplay of the inducible β-lactamase AmpC and the
resistance nodulation cell division (RND) multidrug efﬂux sys-
tems (e.g., MexAB-OprM; Masuda et al., 1999). Benzyl-penicillins
(e.g., amoxicillin) and narrow-spectrum cephalosporins are
labile to hydrolysis and are strong inducers of ampC, lead-
ing to antibiotic degradation, whereas ureidopenicillins (e.g.,
piperacillin) and extended-spectrum cephalosporins are labile
but are weak inducers of ampC (Livermore, 1995). The mexAB-
oprM operon is constitutively expressed in wild-type cells under
usual laboratory conditions, where the operon contributes to
P. aeruginosa’s intrinsic resistance to most β-lactams (except
for imipenem) and many other antimicrobial agents, includ-
ing quinolones, tetracycline, chloramphenicol, and macrolides
(Morita et al., 2001). Blocking of dacB-encoded non-essential
PBP4 determines a highly efﬁcient and complex β-lactam resis-
tance response, triggering the overproduction of AmpC and the
speciﬁc activation of theCreAB (BlrAB) two-component regulator
(Moya et al., 2009).
Carbapenems are an important class of anti-pseudomonal β-
lactams. Carbapenems are strong inducers that are marginally
labile (imipenem) or effectively stable (meropenem; Livermore,
1995). Imipenem also has been shown to strongly induce ampC
gene expression in bioﬁlms (Bagge et al., 2004). In addition,
P. aeruginosa bioﬁlms exposed to imipenem exhibit elevated
expression of genes coding for alginate biosynthesis, causing
thicker and more robust bioﬁlms (Bagge et al., 2004).
Ceftazidime, a PBP3 inhibitor, does not induce ampC gene
expression, but is rather a substrate of AmpC. Ceftazidime
impacts the transcription of a large number of genes in P. aerug-
inosa, including those encoding the SOS response repressor
LexA-like proteins, causing induced mutagenesis and decreas-
ing ciproﬂoxacin toxicity (Blazquez et al., 2006). In addition, this
antimicrobial shows quorum sensing (QS) inhibitory activity,
decreasing the production of a range of QS-regulated viru-
lence factors, in contrast to piperacillin, another PBP3 inhibitor
(Skindersoe et al., 2008) These results imply that the QS inhibitory
activity of ceftazidime likely is not PBP3-dependent (Skindersoe
et al., 2008).
RESPONSES TO FLUOROQUINOLONES
Fluoroquinolones, particularly ciproﬂoxacin, are commonly used
for the treatment of P. aeruginosa infections (Poole, 2011). This
class of agents interacts with complexes composed of DNA
and either of the two target enzymes, DNA gyrase and/or
topoisomerase IV. Primary intrinsic resistance of the wild-type
P. aeruginosa to ﬂuoroquinolones is due to MexAB-OprM as well
as to MexXY-OprM (Morita et al., 2001). The four RND-type
multidrug efﬂux pumps (MexAB-OprM, MexCD-OprJ, MexEF-
OprN, and MexXY-OprM) are well recognized as signiﬁcant
determinants of ﬂuoroquinolone resistance in lab and clinical
isolates (Poole, 2011), although there are several additional chro-
mosomally encoded efﬂux pumps that are able to recognize
ﬂuoroquinolones (e.g.,MexHI-OpmD,MexVW-OprM, theNorM
ortholog; Morita et al., 1998; Li et al., 2003; Sekiya et al., 2003; He
et al., 2004).
The formation of static bioﬁlms increases when P. aeruginosa
cells are incubated in the presence of sub-inhibitory concentra-
tions of ciproﬂoxacin, tobramycin, or tetracycline, while no such
sub-inhibitory effect is detected with members of other antibi-
otic classes, such as carbenicillin, chloramphenicol, or polymyxin
(Hoffman et al., 2005; Linares et al., 2006). However, in the pres-
ence of a sub-inhibitory concentration of ciproﬂoxacin (but not
of tetracycline or tobramycin), P. aeruginosa shows a reduction in
swimming and swarming, both of which are important systems of
bacterial motility and probably related to the pathogenic process
in CF patients (Linares et al., 2006).
Transcriptional responses of P. aeruginosa to sub-inhibitory
and inhibitory concentrations of ciproﬂoxacin demonstrate the
induction or repression of 100s of genes (Brazas and Han-
cock, 2005; Cirz et al., 2006; Brazas et al., 2007). Surprisingly,
genes for bacteriophage-like pyocins are up-regulated and medi-
ate ﬂuoroquinolone susceptibility (Brazas and Hancock, 2005).
At least one-third of up-regulated genes occur in regulons that
are likely controlled by LexA-like SOS response repressor proteins
in response to inhibitory concentrations of ciproﬂoxacin, while
down-regulated genes appear to involve virtually every facet of
cellular metabolism (Cirz et al., 2006; Brazas et al., 2007). The Lon
protease modulates SOS response and consequently ciproﬂoxacin
susceptibility (Breidenstein et al., 2012).
The overall pattern of expression of the DNA replication
enzymes suggests a shift from canonical DNA replication enzymes
to inducible polymerases in response to inhibitory ciproﬂoxacin
concentrations (Cirz et al., 2006). These inhibitory concentra-
tions of ciproﬂoxacin create selection pressure in favor of mutants
with increased ampC expression (Wolter et al., 2007), while
sub-inhibitory levels of ciproﬂoxacin or oﬂoxacin enhance the
frequency of mutation to carbapenem (especially meropenem)
resistance (Tanimoto et al., 2008).
RESPONSES TO AMINOGLYCOSIDES
Aminoglycosides bind to the 30S ribosomal subunit and inter-
fere with protein synthesis, causing mistranslation and ultimately
cell death without lysis (Davis, 1987). APH(3′)-IIb, a chromo-
somal aphA-encoded aminoglycoside phosphoryltransferase, is
likely responsible for the general non-susceptibility of P. aeruginosa
to kanamycin (Hachler et al., 1996), andAPH(3′)-II predominates
in clinical isolates resistant to kanamycin (Poole, 2005). Anti-
pseudomonas aminoglycosides (e.g., amikacin, gentamicin, and
tobramycin) therefore can be used in the treatment of P. aeruginosa
infections (Poole, 2005). Aminoglycoside uptake and subsequent
action within bacterial cells is a complex process that involves
Lipopolysaccharides (LPS) binding and outer-membrane per-
meation, cytoplasmic membrane traversal driven by membrane
potential, and ribosome disruption, leading to the production
of membrane-damaging mistranslated polypeptides (Davis, 1987;
Krahn et al., 2012). Primary intrinsic and adaptive resistance to
aminoglycosides is due to the MexXY multidrug efﬂux system in
laboratory and clinical isolates (Morita et al., 2012b). The antag-
onism of aminoglycosides by divalent cations Mg2+ and Ca2+
is well documented in P. aeruginosa, and occurs via a process
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that requires the MexXY multidrug efﬂux system (Mao et al.,
2001; Morita et al., 2012a). In wild-type P. aeruginosa cells, the
MexXYefﬂux system is inducible by sub-inhibitory concentrations
of aminoglycoside- and ribosome-targeting antimicrobials (e.g.,
chloramphenicol and tetracycline), a process shown to be involved
in expression of the PA5471 gene product [recently renamed
ArmZ, for anti-repressor MexZ (Morita et al., 2006; Hay et al.,
2013)] The PA5471 system also is inducible through interference
via translation of the gene’s leader peptide, PA5471.1 (Morita et al.,
2009). Very recently a clinical strain overproducing MexXY was
reported also to harbor a 7-bp deletion in the coding sequence of
the leader peptide involved in ribosome-dependent, translational
attenuation of PA5471 expression (Guénard et al., 2013).
Transcriptomic analyses conﬁrm that aminoglycosides impact
the expression of a myriad of genes (Kindrachuk et al., 2011).
While prolonged exposure to sub-inhibitory concentrations of
tobramycin causes increased levels of expression, predominantly
of the mexXY efﬂux pump genes, the greatest increases in
gene expression levels in response to lethal concentrations of
tobramycin involve a number of P. aeruginosa heat shock genes
(e.g., htpG, ibpA, groES, and asrA; Kindrachuk et al., 2011). Under
these conditions, the likely intracellular ATP-dependent AsrA pro-
tease is noteworthy because of its modest positive impact on
aminoglycoside resistance (Kindrachuk et al., 2011). The Lon
protease also is inducible by aminoglycosides (Marr et al., 2007).
Sub-inhibitory concentrations of aminoglycosides, especially
tobramycin, induce bioﬁlm formation in P. aeruginosa (Hoffman
et al., 2005). Notably, the aminoglycoside tobramycin also induces
both swimming and swarming of P. aeruginosa (Linares et al.,
2006). Also induced is the aminoglycoside response regulator (arr)
gene, which is predicted to encode an inner membrane phospho-
diesterase. The Arr substrate is cyclic di-guanosine monophos-
phate (c-di-GMP), a bacterial second messenger that regulates
cell surface adhesiveness; c-di-GMP is essential for this induc-
tion and contributes to bioﬁlm-speciﬁc aminoglycoside resistance
(Hoffman et al., 2005).
RESPONSES TO POLYMYXINS
Owing to the increased prevalence of multidrug-resistant P.
aeruginosa, polymyxin B and colistin (also called polymyxin E),
belonging to a family of antimicrobial cyclic oligopeptides, have
returned to favor as a last-resort treatment option, although these
agents have strong side effects (e.g., nephrotoxicity) with high
incidence (Poole, 2011). Very recently, the polymyxin mutant pre-
vention concentrations (MPCs) for P. aeruginosa were shown to
be very high (≥64 μg/ml), even for susceptible isolates (i.e., with
minimum inhibitory concentration (MIC) ranges of 1–2 μg/ml;
Choi and Ko, 2013). In the MPC studies, mutation to polymyxin
resistance apparently can result from a single mutation (Choi and
Ko, 2013).
The mechanism of action of polymyxins involves an initial
stage of interaction with the lipid A of the LPS, leading to self-
promoted uptake of polymyxins across the membrane, followed
by cell death (Zhang et al., 2000; Fernandez et al., 2013). The most
commonmechanismof resistance to polymyxinhas been shown to
arise from modiﬁcation of LPS lipid A with 4-amino-L-arabinose,
a process that has been seen both in in vitro-selected mutants
and in CF isolates; other unknown mechanisms remain under
investigation (Miller et al., 2011; Poole, 2011; Moskowitz et al.,
2012). This modiﬁcation is carried out by the products of the arn-
BCADTEF-ugd operon, otherwise known as pmrHFIJKLM-ugd
(McPhee et al., 2003; Yan et al., 2007). The two-component ParRS
regulator leads to the induction of the LPS modiﬁcation operon
in response to sub-inhibitory concentrations of polymyixin B and
colistin (Fernandez et al., 2010).
Approximately 0.5% of genes showed signiﬁcantly altered
expression upon exposure to sub-inhibitory concentration of col-
istin (Cummins et al., 2009), a frequency that is no less dramatic
than that seen with the other anti-pseudomonas agents (e.g., cef-
tazidime, ciproﬂoxacin, and tobramycin) described above. The
most striking alterations were up-regulation of the Pseudomonas
quinolone signal (PQS) biosynthetic genes such as the pqsABCDE
operon, the phenazine biosynthetic operon, and the arn operon
(Cummins et al., 2009).
RESPONSES TO THE MAJOR HUMAN CATIONIC HOST
DEFENSE PEPTIDE, LL-37
The major human cationic host defense peptide LL37 [a.k.a.
hCAP-18, FALL-39, or cathelicidin antimicrobial peptide
(CAMP)], a 37-amino-acid, 18-kDa peptide, is encoded by the
cathelicidin gene (CAMP) and was originally identiﬁed in humans
(Kosciuczuk et al., 2012). Sub-inhibitory concentration of LL-
37 (1/4–1/128 of the MIC of 64 μg/ml) were shown to prevent
bioﬁlm formation by decreasing the attachment of P. aeruginosa
cells, stimulating twitching motility, and inﬂuencing two major
QS systems (Las and Rhl), leading to the down-regulation of genes
essential for bioﬁlm development (Overhage et al., 2008). Similar
results were obtained using the bovine neutrophil peptide indoli-
cidin, but no inhibitory effects on bioﬁlm formation were detected
using sub-inhibitory concentrations of themousepeptideCRAMP
(67% identical with LL-37), polymyxin B,or the bovine bactenecin
homolog Bac2A (Overhage et al., 2008).
RESPONSES TO MACROLIDES
Macrolides such as erythromycin and azithromycin are widely
used antibiotics that block translation by binding to the 50S ribo-
somal subunit. P. aeruginosa cells are intrinsically resistant to
macrolides when tested in standard broth culture; for instance, the
MIC of erythromycin for P. aeruginosa PAO1 is about 512 μg/mL
in Mueller-Hinton broth (e.g., Morita et al., 2001; Buyck et al.,
2012). Nonetheless, low-dose macrolides such as azithromycin
are effective treatments in patients with chronic lung infections
(Jaffe et al., 1998; Kudoh et al., 1998). Even at concentrations
(e.g., 2 μg/ml of azithromycin) far below the MIC, macrolides
inhibit the QS circuitry of P. aeruginsoa strain PAO1, leading to
a reduction in virulence factor production (Tateda et al., 2001).
Low-dose azithromycin shows bactericidal activity for P. aerugi-
nosa bioﬁlms, but selects for nfxB mutants, which overproduce
the MexCD-OprJ efﬂux pump (Mulet et al., 2009). Notably, the
AmpC β-lactamase produced by nfxB mutants is protective in
bioﬁlm growth, although over expression of the MexCD-OprJ
pump is known to impairP. aeruginosa’s intrinsic resistance,which
is dependent on the MexXY/MexAB-OprM efﬂux pump and the
AmpC (Mulet et al., 2011).
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Genome-wide approaches have revealed the QS antagonis-
tic activities of azithromycin (e.g., inhibition of QS, reduction
of virulence factor production, and strong induction of type-
III secretion systems; Nalca et al., 2006; Skindersoe et al., 2008).
This modulation causes decreased expression of the genes encod-
ing the MexAB-OprM efﬂux pump in P. aeruginosa (Sugimura
et al., 2008). Azithromycin inhibits expression of the small RNAs
rsmY and rsmZ, a process that depends on the GacA/Rsm sig-
nal transduction pathway; this pathway is known to positively
control P. aeruginosa QS (Perez-Martinez and Haas, 2011). Both
effects of azithromycin on QS (quorum factor-dependent viru-
lence factor production and cell death) require azithromycin to
interact with ribosomes (Kohler et al., 2007). The stationary-phase
killing of azithromycin is further enhanced by the production of
rhamnolipids, which likely facilitate macrolide uptake (Kohler
et al., 2007). The mode of action of azithromycin in vivo also
is demonstrated through mutations in 23S rRNA that confer
azithromycin resistance in bacterial isolates of P. aeruginosa in
chronically infected CF patients (Marvig et al., 2012). The clini-
cal efﬁcacy of macrolides in treating pseudomonal infections can
be partially explained by the increased susceptibility of P. aerug-
inosa to these compounds in eukaryotic cell culture media and
biological ﬂuids, due to decreased oprM expression and increased
outer-membrane permeability (Buyck et al., 2012).
RESPONSES TO TETRACYCLINES AND CHLORAMPHENICOL
Tetracyclines are bacteriostatic antibiotics based on a hydroan-
thracene nucleus, which contains four fused rings. The class also
includes glycylcyclines (e.g., tigecycline), a group of semisynthetic
tetracycline derivatives containing a glycylamido substitution at
position 9 (Yao and Moellering, 2011). Tetracyclines enter bacte-
ria by an energy-dependent process and bind reversibly to the 30S
ribosomal subunit, preventing the attachment of aminoacyl-tRNA
to the ribosomal acceptor A-site in the RNA-ribosome complex
(Yao and Moellering, 2011). P. aeruginosa is intrinsically resistant
to tetracyclines and glycylcyclines due to theMexAB/MexXY efﬂux
systems (Morita et al., 2001; Dean et al., 2003). Sub-inhibitory
concentrations of tetracycline and tigecycline induce the MexXY
RND efﬂux system via a mechanism dependent on the riboso-
mal inhibitor-inducible PA5471 gene product (Dean et al., 2003;
Morita et al., 2006).
Tetracycline increases bioﬁlm formation aswell as ciproﬂoxacin
and tobramycin, as described above (Linares et al., 2006). Surpris-
ingly, incubation with tetracycline at concentrations (∼1 μg/ml)
that do not decrease the growth rate of P. aeruginosa increases
the expression of type-III secretion system (T3SS) genes exsA and
exoS, and the presence of tetracycline increases the cytotoxicity of
P. aeruginosa by nearly 4-fold (Linares et al., 2006). The T3SS is
a mechanism by which bacterial pathogens can deliver effectors
directly into the cytoplasm of the eukaryotic host cell (Hauser,
2009). Expression of genes forming the T3SS regulon is triggered
by ExaA (Hauser, 2009), a transcriptional activator that auto-
regulates its own expression by a feedback mechanism (Hauser,
2009). ExoS corresponds to a T3SS-secreted toxin (Hauser, 2009).
Chloramphenicol is a bacteriostatic agent that inhibits pro-
tein synthesis by binding reversibly to the peptidyltransferase
component of the 50S ribosomal subunit and preventing the
transpeptidation process of peptide chain elongation (Yao and
Moellering, 2011). P. aeruginosa is usually intrinsically resistant to
chloramphenicol, in part due to the MexAB-OprM efﬂux system
(Morita et al., 2001). In addition, sub-inhibitory concentrations
of chloramphenicol induce the MexXY efﬂux system via a mech-
anism dependent on the ribosomal inhibitor-inducible PA5471
gene product (Morita et al., 2006). This effect is reminiscent of the
induction of the MexEF-OprN efﬂux system (via the MexT activa-
tor) in response to chloramphenicol and nitrosative stress (Fetar
et al., 2011). Chloramphenicol is a nitro-aromatic antimicrobial
and resembles a nitrosative stress product (Fetar et al., 2011).
RESPONSE TO BIOCIDES
Pseudomonas aeruginosa also has been reported to contaminate
disinfectants (e.g., chlorhexidine, benzalkonium, and triclosan) in
hospital or other such environments, thereby compromising the
disinfectant’s ability to reduce or eliminate bacterial contamina-
tion. Chlorhexidine and benzalkonium are a cationic biguanide
and a nitrogen-based quaternary ammonium compound, respec-
tively. These biocides function by affecting the cell membrane,
resulting in lysis and the loss of cytoplasmic material (Poole,
2002). The RND-type MexCD-OprJ multidrug efﬂux pump is
induced by sub-inhibitory concentrations of disinfectants such as
benzalkonium chloride or chlorhexidine (Morita et al., 2003), a
process that is dependent upon the AlgU stress response factor
(Fraud et al., 2008). Global transcriptome response to chlorhexi-
dine includes up-regulation of the mexCD-oprJ and oprH-phoPQ
operons and down-regulation of genes encoding proteins involved
in membrane transport, oxidative phosphorylation, electron
transport, and DNA repair (Nde et al., 2009). A P. aeruginosa
variant highly adapted to benzalkonium showed increased resis-
tance to ﬂuoroquinolones, owing to mutations in the quinolone
resistance-determining region of gyrA and to mutations in genes
(mexR and nfxB) that encode repressors of mexAB-oprM and
mexCD-oprJ, respectively (Mc Cay et al., 2010). Development of
chlorhexidine-tolerant sub-populations in P. aeruginosa bioﬁlms
also is dependent on the mexCD-oprJ genes (Chiang et al., 2012).
Triclosan speciﬁcally inhibits fatty acid synthesis through inhi-
bition of bacterial enoyl–acyl carrier protein reductase, although
P. aeruginosa is intrinsically resistant to triclosan due to the
structure of the pseudomonal FabV protein (a triclosan-resistant
enoyl–acyl carrier protein reductase) and active efﬂux. This innate
resistance stems from at least ﬁve RND efﬂux pumps, including
MexAB-OprM (Mima et al., 2007; Zhu et al., 2010). In P. aerugi-
nosa mutant cells lacking the mexAB-oprM genes, sub-inhibitory
concentrations of triclosan lead to alterations in the expression
of almost half the genome, with 28% of genes being signiﬁ-
cantly up-regulated and 16% being signiﬁcantly down-regulated
(Chuanchuen and Schweizer, 2012). QS-regulating genes are
among the most strongly down-regulated, and surprisingly, iron
homeostasis is completely blocked in triclosan-exposed cells,
thus mimicking conditions with excess iron (Chuanchuen and
Schweizer, 2012).
SUMMING UP AND FURTHER PROSPECTS
The primary biological responses of P. aeruginosa to sub-
inhibitory concentrations of antimicrobials are summarized
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Table 1 | Biological responses of P. aeruginosa exposed to various antimicrobials at levels below the inhibitory concentrations.
Antimicrobials Biological responses References
β-lactams Induction of the AmpC β-lactamase(some β-lactams are inducers, but others are not) Livermore (1995)
Carbapenems Formation of thicker and more robust bioﬁlms(induction of alginate biosynthesis) Bagge et al. (2004)
Ceftazidime Induction of mutagenesis and decreasing ciproﬂoxacin toxicity Blazquez et al. (2006)
Inhibition of quorum sensing Skindersoe et al. (2008)
Fluoroquinolones Induction of bioﬁlm formation Linares et al. (2006)
Reduction in swimming and swarming Linares et al. (2006)
Induction of SOS response Brazas and Hancock (2005)
Up-regulation of the bacteriophage-like pyocins Brazas and Hancock (2005)
Shift from canonical DNA replication enzymes to inducible polymerases Cirz et al. (2006)
Enhancement of mutation frequency to β-lactam resistance. Wolter et al. (2007), Tanimoto
et al. (2008)
Protein synthesis inhibitors Induction of the MexXY efﬂux system Morita et al. (2012b)
Aminoglycosides Induction of heat shock genes Kindrachuk et al. (2011)
Induction of bioﬁlm formation Hoffman et al. (2005)
Induction of swimming and swarming Linares et al. (2006)
Induction of the Lon protease Marr et al. (2007)
Macrolides Quorum sensing antagonistic activity(reduction in virulence factor) Tateda et al. (2001)
Induction of theT3SS Nalca et al. (2006)
Down-regulation of the MexAB-OprM pump Sugimura et al. (2008)
Tetracycline Induction of bioﬁlm formation Linares et al. (2006)
Induction of theT3SS and cytotoxicity Linares et al. (2006)
Chloramphenicol Induction of the MexEF-OprN efﬂux pump Fetar et al. (2011)
Polymyxins Modiﬁcation of LPS lipid A with 4-amino-L-arabinose Fernandez et al. (2010)
Up-regulation of the PQS biosynthetic genes Cummins et al. (2009)
Chlorhexidine Induction of the MexCD-OprJ efﬂux pump Morita et al. (2003)
Induction of the oprH-phoPQ operon Nde et al. (2009)
in Table 1. Interestingly, clinically useful anti-pseudomonas
agents (carbapenems, ﬂuoroquinolones, and aminoglycosides) are
known to efﬁciently kill P. aeruginosa planktonic cells when used
properly, but lead to more severe bioﬁlm development upon expo-
sure at sub-inhibitory concentrations. This pattern means that
optimization of anti-pseudomonas chemotherapy is critical; in
the absence of such optimization, chemotherapy fails to treat the
infection and readily selects multidrug-resistant P. aeruginosa. By
contrast, macrolides (which are not effective against P. aeruginosa
planktonic cells because of the planktonic cells’ intrinsic resis-
tance) provide activity that is antagonistic to QS, thereby reducing
pseudomonal virulence. These ﬁndings regarding responses to
antimicrobial agents suggest a route toward conquering P. aerug-
inosa infections. For example, macrolides have been shown to
augment the in vitro activity of anti-pseudomonas agents against
bioﬁlms (Lutz et al., 2012).
We are aware of potential molecular targets for novel anti-
pseudomonas agents, including essential genes (Morita et al.,
2010). Novel class anti-pseudomonas agents should be expected
to minimize a severe situation in which few agents are effective
against these organisms. However, it is a much more difﬁcult task
to develop novel class antimicrobials for P. aeruginosa because
of the presence of low membrane permeability and the RND
multidrug efﬂux pumps. In addition this organism has the ability
to adapt to various stresses, including sub-inhibitory antimicro-
bial exposure, by recruiting antimicrobial resistance mechanisms,
notably that of RND efﬂux systems such as the MexXY system.
While many laboratories are currently screening, so far no efﬂux
pump inhibitors have been made available for clinical settings.
Screening for novel antibacterial agents, including efﬂux pump
inhibitors, is currently in progress in many laboratories, including
our own.
ACKNOWLEDGMENTS
This work was supported in part by a Grant-in-Aid for Young
Scientists (B) (Kakenhi 23790106) from the Japan Society for the
Promotion of Science, and by a research grant from the Institute
of Pharmaceutical Life Sciences, Aichi Gakuin University.
REFERENCES
Aminov, R. I. (2013). Biotic acts of antibiotics. Front. Microbiol. 4:241. doi:
10.3389/fmicb.2013.00241
www.frontiersin.org January 2014 | Volume 4 | Article 422 | 5
“fmicb-04-00422” — 2014/1/6 — 20:15 — page 6 — #6
Morita et al. Low-dose antimicrobials against Pseudomonas aeruginosa
Bagge, N., Schuster, M., Hentzer, M., Ciofu, O., Givskov, M., Greenberg, E. P., et al.
(2004). Pseudomonas aeruginosa bioﬁlms exposed to imipenem exhibit changes in
global gene expression and beta-lactamase and alginate production. Antimicrob.
Agents Chemother. 48, 1175–1187. doi: 10.1128/AAC.48.4.1175-1187.2004
Blazquez, J., Gomez-Gomez, J. M., Oliver, A., Juan, C., Kapur, V., and
Martin, S. (2006). PBP3 inhibition elicits adaptive responses in Pseu-
domonas aeruginosa. Mol. Microbiol. 62, 84–99. doi: 10.1111/j.1365-2958.2006.
05366.x
Brazas, M. D., Breidenstein, E. B., Overhage, J., and Hancock, R. E. (2007).
Role of lon, an ATP-dependent protease homolog, in resistance of Pseudomonas
aeruginosa to ciproﬂoxacin. Antimicrob. Agents Chemother. 51, 4276–4283. doi:
10.1128/AAC.00830-07
Brazas,M. D., and Hancock, R. E. (2005). Ciproﬂoxacin induction of a susceptibility
determinant inPseudomonas aeruginosa.Antimicrob. AgentsChemother. 49, 3222–
3227. doi: 10.1128/AAC.49.8.3222-3227.2005
Breidenstein, E. B., Bains, M., and Hancock, R. E. (2012). Involvement of the lon
protease in the SOS response triggered by ciproﬂoxacin in Pseudomonas aerug-
inosa PAO1. Antimicrob. Agents Chemother. 56, 2879–2887. doi: 10.1128/AAC.
06014-11
Buyck, J. M., Plesiat, P., Traore, H., Vanderbist, F., Tulkens, P. M., and Van Bambeke,
F. (2012). Increased susceptibility of Pseudomonas aeruginosa to macrolides and
ketolides in eukaryotic cell culture media and biological ﬂuids due to decreased
expression of oprM and increased outer-membrane permeability. Clin. Infect.
Dis. 55, 534–542. doi: 10.1093/cid/cis473
Chiang, W. C., Pamp, S. J., Nilsson, M., Givskov, M., and Tolker-Nielsen, T.
(2012). The metabolically active subpopulation in Pseudomonas aeruginosa
bioﬁlms survives exposure to membrane-targeting antimicrobials via distinct
molecular mechanisms. FEMS Immunol. Med. Microbiol. 65, 245–256. doi:
10.1111/j.1574-695X.2012.00929.x
Choi, M. J., and Ko, K. S. (2013). Mutant prevention concentrations of colistin
for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumo-
niae clinical isolates. J. Antimicrob. Chemother. 69, 275–277. doi: 10.1093/jac/
dkt315
Chuanchuen, R., and Schweizer, H. P. (2012). Global transcriptional responses
to triclosan exposure in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 40,
114–122. doi: 10.1016/j.ijantimicag.2012.04.008
Cirz, R. T., O’Neill, B. M., Hammond, J. A., Head, S. R., and Romesberg, F. E.
(2006). Deﬁning the Pseudomonas aeruginosa SOS response and its role in the
global response to the antibiotic ciproﬂoxacin. J. Bacteriol. 188, 7101–7110. doi:
10.1128/JB.00807-06
Cummins, J., Reen, F. J., Baysse, C., Mooij, M. J., and O’Gara, F. (2009). Subin-
hibitory concentrations of the cationic antimicrobial peptide colistin induce the
Pseudomonas quinolone signal in Pseudomonas aeruginosa. Microbiology 155,
2826–2837. doi: 10.1099/mic.0.025643-0
Davis, B.D. (1987). Mechanismof bactericidal action of aminoglycosides. Microbiol.
Rev. 51, 341–350.
Dean, C. R.,Visalli,M. A., Projan, S. J., Sum, P. E., and Bradford, P. A. (2003). Efﬂux-
mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.
Antimicrob. Agents Chemother. 47, 972–978. doi: 10.1128/AAC.47.3.972-978.2003
Fernandez, L., Alvarez-Ortega, C.,Wiegand, I., Olivares, J., Kocincova, D., Lam, J. S.,
et al. (2013). Characterization of the polymyxin B resistome of Pseudomonas
aeruginosa. Antimicrob. Agents Chemother. 57, 110–119. doi: 10.1128/AAC.
01583-12
Fernandez, L.,Gooderham,W. J., Bains,M.,McPhee, J. B.,Wiegand, I., andHancock,
R. E. (2010). Adaptive resistance to the “last hope” antibiotics polymyxin B and
colistin in Pseudomonas aeruginosa is mediated by the novel two-component
regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54, 3372–3382. doi:
10.1128/aac.00242-210
Fetar, H., Gilmour, C., Klinoski, R., Daigle, D. M., Dean, C. R., and Poole,
K. (2011). mexEF-oprN multidrug efﬂux operon of Pseudomonas aeruginosa:
regulation by the MexT activator in response to nitrosative stress and chlo-
ramphenicol. Antimicrob. Agents Chemother. 55, 508–514. doi: 10.1128/AAC.
00830-10
Fraud, S., Campigotto, A. J., Chen, Z., and Poole, K. (2008). MexCD-OprJ mul-
tidrug efﬂux system of Pseudomonas aeruginosa: involvement in chlorhexidine
resistance and induction by membrane-damaging agents dependent upon the
AlgU stress response sigma factor. Antimicrob. Agents Chemother. 52, 4478–4482.
doi: 10.1128/AAC.01072-08
Guénard, S.,Muller, C.,Monlezun, L., Benas, P., Broutin, I., Jeannot, K., et al. (2013).
Multiple mutations lead to MexXY/OprM-dependent aminoglycoside resistance
in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58,
221–228. doi: 10.1128/AAC.01252-13
Hachler, H., Santanam, P., and Kayser, F. H. (1996). Sequence and charac-
terization of a novel chromosomal aminoglycoside phosphotransferase gene,
aph (′)-IIb, in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40,
1254–1256.
Hauser, A. R. (2009). The type III secretion system of Pseudomonas aeruginosa:
infection by injection. Nat. Rev. Microbiol. 7, 654–665. doi: 10.1038/nrmicro2199
Hay, T., Fraud, S., Lau, C. H., Gilmour, C., and Poole, K. (2013). Antibiotic
inducibility of the mexXY multidrug efﬂux operon of Pseudomonas aerugi-
nosa: involvement of the MexZ anti-repressor ArmZ. PLoS ONE 8:e56858. doi:
10.1371/journal.pone.0056858
He, G. X., Kuroda, T., Mima, T., Morita, Y., Mizushima, T., and Tsuchiya, T. (2004).
An H(+)-coupled multidrug efﬂux pump, PmpM, a member of the MATE family
of transporters, from Pseudomonas aeruginosa. J. Bacteriol. 186, 262–265. doi:
10.1128/JB.186.1.262-265.2004
Hoffman, L. R., D’Argenio, D. A., MacCoss, M. J., Zhang, Z., Jones, R. A., and Miller,
S. I. (2005). Aminoglycoside antibiotics induce bacterial bioﬁlm formation.
Nature 436, 1171–1175. doi: 10.1038/nature03912
Jaffe, A., Francis, J., Rosenthal, M., and Bush, A. (1998). Long-term azithromycin
may improve lung function in children with cystic ﬁbrosis. Lancet 351, 420. doi:
10.1016/S0140-6736(05)78360-4
Kindrachuk,K.N., Fernandez, L., Bains,M., andHancock,R. E. (2011). Involvement
of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response
to tobramycin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55,
1874–1882. doi: 10.1128/AAC.00935-10
Kohler, T., Dumas, J. L., and Van Delden, C. (2007). Ribosome protection pre-
vents azithromycin-mediated quorum-sensing modulation and stationary-phase
killing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51, 4243–4248.
doi: 10.1128/AAC.00613-07
Kosciuczuk, E. M., Lisowski, P., Jarczak, J., Strzalkowska, N., Jozwik, A.,
Horbanczuk, J., et al. (2012). Cathelicidins: family of antimicrobial pep-
tides. A review. Mol. Biol. Rep. 39, 10957–10970. doi: 10.1007/s11033-012-
1997-x
Krahn, T., Gilmour, C., Tilak, J., Fraud, S., Kerr, N., Lau, C. H., et al. (2012).
Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother. 56, 5591–5602. doi: 10.1128/AAC.01446-12
Kudoh, S., Azuma, A., Yamamoto, M., Izumi, T., and Ando, M. (1998).
Improvement of survival in patients with diffuse panbronchiolitis treated with
low-dose erythromycin. Am. J. Respir. Crit. Care Med. 157, 1829–1832. doi:
10.1164/ajrccm.157.6.9710075
Li, Y., Mima, T., Komori, Y., Morita, Y., Kuroda, T., Mizushima, T., et al.
(2003). A new member of the tripartite multidrug efﬂux pumps, MexVW-
OprM, in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 52, 572–575. doi:
10.1093/jac/dkg390
Linares, J. F., Gustafsson, I., Baquero, F., and Martinez, J. L. (2006). Antibiotics as
intermicrobial signaling agents instead of weapons. Proc. Natl. Acad. Sci. U.S.A.
103, 19484–19489. doi: 10.1073/pnas.0608949103
Livermore,D.M. (1995). beta-Lactamases in laboratory and clinical resistance. Clin.
Microbiol. Rev. 8, 557–584.
Lutz, L., Pereira, D. C., Paiva, R. M., Zavascki, A. P., and Barth, A. L. (2012).
Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal
agents against Pseudomonas aeruginosa from cystic ﬁbrosis patients in bioﬁlm.
BMC Microbiol. 12:196. doi: 10.1186/1471-2180-12-196
Mao, W., Warren, M. S., Lee, A., Mistry, A., and Lomovskaya, O. (2001). MexXY-
OprM efﬂux pump is required for antagonism of aminoglycosides by divalent
cations in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45, 2001–
2007. doi: 10.1128/AAC.45.7.2001-2007.2001
Marr, A. K., Overhage, J., Bains, M., and Hancock, R. E. (2007). The Lon
protease of Pseudomonas aeruginosa is induced by aminoglycosides and is
involved in bioﬁlm formation and motility. Microbiology 153, 474–482. doi:
10.1099/mic.0.2006/002519-0
Marvig, R. L., Sondergaard, M. S., Damkiaer, S., Hoiby, N., Johansen, H. K., Molin,
S., et al. (2012). Mutations in 23S rRNA confer resistance against azithromycin
in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56, 4519–4521. doi:
10.1128/AAC.00630-12
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy January 2014 | Volume 4 | Article 422 | 6
“fmicb-04-00422” — 2014/1/6 — 20:15 — page 7 — #7
Morita et al. Low-dose antimicrobials against Pseudomonas aeruginosa
Masuda, N., Gotoh, N., Ishii, C., Sakagawa, E., Ohya, S., and Nishino, T. (1999).
Interplay between chromosomal beta-lactamase and theMexAB-OprMefﬂux sys-
tem in intrinsic resistance to beta-lactams inPseudomonas aeruginosa.Antimicrob.
Agents Chemother. 43, 400–402.
Mc Cay, P. H., Ocampo-Sosa, A. A., and Fleming, G. T. (2010). Effect of subin-
hibitory concentrations of benzalkonium chloride on the competitiveness of
Pseudomonas aeruginosa grown in continuous culture. Microbiology 156, 30–38.
doi: 10.1099/mic.0.029751-0
McPhee, J. B., Lewenza, S., and Hancock, R. E. (2003). Cationic antimicro-
bial peptides activate a two-component regulatory system, PmrA-PmrB, that
regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseu-
domonas aeruginosa. Mol. Microbiol. 50, 205–217. doi: 10.1046/j.1365-2958.2003.
03673.x
Miller, A. K., Brannon, M. K., Stevens, L., Johansen, H. K., Selgrade, S. E., Miller,
S. I., et al. (2011). PhoQ mutations promote lipid A modiﬁcation and polymyxin
resistance of Pseudomonas aeruginosa found in colistin-treated cystic ﬁbrosis
patients. Antimicrob. Agents Chemother. 55, 5761–5769. doi: 10.1128/AAC.
05391-11
Mima, T., Joshi, S., Gomez-Escalada, M., and Schweizer, H. P. (2007). Identiﬁcation
and characterization of TriABC-OpmH, a triclosan efﬂux pump of Pseudomonas
aeruginosa requiring two membrane fusion proteins. J. Bacteriol. 189, 7600–7609.
doi: 10.1128/JB.00850-07
Morita, Y., Gilmour, C., Metcalf, D., and Poole, K. (2009). Translational control
of the antibiotic inducibility of the PA5471 gene required for mexXY multidrug
efﬂux gene expression in Pseudomonas aeruginosa. J. Bacteriol. 191, 4966–4975.
doi: 10.1128/JB.00073-09
Morita, Y., Kimura, N., Mima, T., Mizushima, T., and Tsuchiya, T. (2001). Roles
of MexXY- and MexAB-multidrug efﬂux pumps in intrinsic multidrug resis-
tance of Pseudomonas aeruginosa PAO1. J. Gen. Appl. Microbiol. 47, 27–32. doi:
10.2323/jgam.47.27
Morita,Y., Kodama, K., Shiota, S.,Mine, T., Kataoka,A.,Mizushima, T., et al. (1998).
NorM, a putative multidrug efﬂux protein, of Vibrio parahaemolyticus and its
homolog in Escherichia coli. Antimicrob. Agents Chemother. 42, 1778–1782.
Morita, Y., Murata, T., Mima, T., Shiota, S., Kuroda, T., Mizushima, T., et al. (2003).
Induction of mexCD-oprJ operon for a multidrug efﬂux pump by disinfectants in
wild-type Pseudomonas aeruginosa PAO1. J. Antimicrob. Chemother. 51, 991–994.
doi: 10.1093/jac/dkg173
Morita, Y., Narita, S., Tomida, J., Tokuda, H., and Kawamura, Y. (2010). Appli-
cation of an inducible system to engineer unmarked conditional mutants of
essential genes of Pseudomonas aeruginosa. J. Microbiol. Methods 82, 205–213.
doi: 10.1016/j.mimet.2010.06.001
Morita, Y., Sobel, M. L., and Poole, K. (2006). Antibiotic inducibility of the
MexXY multidrug efﬂux system of Pseudomonas aeruginosa: involvement of
the antibiotic-inducible PA5471 gene product. J. Bacteriol. 188, 1847–1855. doi:
10.1128/JB.188.5.1847-1855.2006
Morita,Y., Tomida, J., andKawamura,Y. (2012a). MexXYmultidrug efﬂux system of
Pseudomonas aeruginosa. Front. Microbiol. 3:408. doi: 10.3389/fmicb.2012.00408
Morita, Y., Tomida, J., and Kawamura, Y. (2012b). Primary mechanisms medi-
ating aminoglycoside resistance in the multidrug-resistant Pseudomonas aerug-
inosa clinical isolate PA7. Microbiology 158, 1071–1083. doi: 10.1099/mic.0.
054320-0
Moskowitz, S. M., Brannon, M. K., Dasgupta, N., Pier, M., Sgambati, N., Miller, A.
K., et al. (2012). PmrB mutations promote polymyxin resistance of Pseudomonas
aeruginosa isolated from colistin-treated cystic ﬁbrosis patients. Antimicrob.
Agents Chemother. 56, 1019–1030. doi: 10.1128/AAC.05829-11
Moya, B., Dotsch, A., Juan, C., Blazquez, J., Zamorano, L., Haussler, S., et al.
(2009). Beta-lactam resistance response triggered by inactivation of a nonessen-
tial penicillin-binding protein. PLoS Pathog. 5:e1000353. doi: 10.1371/jour-
nal.ppat.1000353
Mulet, X., Macia, M. D., Mena, A., Juan, C., Perez, J. L., and Oliver, A. (2009).
Azithromycin in Pseudomonas aeruginosa bioﬁlms: bactericidal activity and
selection of nfxB mutants. Antimicrob. Agents Chemother. 53, 1552–1560. doi:
10.1128/AAC.01264-08
Mulet, X., Moya, B., Juan, C., Macia, M. D., Perez, J. L., Blazquez, J., et al. (2011).
Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mech-
anisms in planktonic but not bioﬁlm growth. Antimicrob. Agents Chemother. 55,
4560–4568. doi: 10.1128/AAC.00519-11
Nalca, Y., Jansch, L., Bredenbruch, F., Geffers, R., Buer, J., and Haussler, S. (2006).
Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aerug-
inosa PAO1: a global approach. Antimicrob. Agents Chemother. 50, 1680–1688.
doi: 10.1128/AAC.50.5.1680-1688.2006
Nde, C. W., Jang, H. J., Toghrol, F., and Bentley,W. E. (2009). Global transcriptomic
response of Pseudomonas aeruginosa to chlorhexidine diacetate. Environ. Sci.
Technol. 43, 8406–8415. doi: 10.1021/es9015475
Overhage, J., Campisano, A., Bains, M., Torfs, E. C., Rehm, B. H., and
Hancock, R. E. (2008). Human host defense peptide LL-37 prevents bac-
terial bioﬁlm formation. Infect. Immun. 76, 4176–4182. doi: 10.1128/IAI.
00318-08
Perez-Martinez, I., and Haas, D. (2011). Azithromycin inhibits expression of
the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aerug-
inosa. Antimicrob. Agents Chemother. 55, 3399–3405. doi: 10.1128/AAC.
01801-10
Poole, K. (2002). Mechanisms of bacterial biocide and antibiotic resistance. Symp.
Ser. Soc. Appl. Microbiol. 55S–64S. doi: 10.1046/j.1365-2672.92.5s1.8.x
Poole, K. (2004). Resistance to beta-lactam antibiotics. Cell. Mol. Life Sci. 61, 2200–
2223. doi: 10.1007/s00018-004-4060-9
Poole, K. (2005). Aminoglycoside resistance in Pseudomonas aeruginosa. Antimi-
crob. Agents Chemother. 49, 479–487. doi: 10.1128/AAC.49.2.479-487.
2005
Poole, K. (2011). Pseudomonas aeruginosa: resistance to the max. Front. Microbiol.
2:65. doi: 10.3389/fmicb.2011.00065
Schurek, K. N., Breidenstein, E. B. M., and Hancock, R. E. W. (2012). “Pseudomonas
aeruginosa: a persistent pathogen in cystic ﬁbrosis and hospital-associated infec-
tions,” in Antibiotic Discovery and Development, Vol. 1, eds T. J. Dougherty and
M. J. Pucci (New York: Springer), 679–715.
Sekiya, H., Mima, T., Morita, Y., Kuroda, T., Mizushima, T., and Tsuchiya,
T. (2003). Functional cloning and characterization of a multidrug efﬂux
pump, mexHI-opmD, from a Pseudomonas aeruginosa mutant. Antimi-
crob. Agents Chemother. 47, 2990–2992. doi: 10.1128/AAC.47.9.2990-2992.
2003
Skindersoe, M. E., Alhede, M., Phipps, R., Yang, L., Jensen, P. O., Rasmussen, T. B.,
et al. (2008). Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother. 52, 3648–3663. doi: 10.1128/AAC.01230-07
Sugimura, M., Maseda, H., Hanaki, H., and Nakae, T. (2008). Macrolide antibiotic-
mediated down regulation of MexAB-OprM efﬂux pump expression in Pseu-
domonas aeruginosa. Antimicrob. Agents Chemother. 52, 4141–4144. doi: 10.1128/
AAC.00511-08
Tanimoto, K., Tomita, H., Fujimoto, S., Okuzumi, K., and Ike, Y. (2008).
Fluoroquinolone enhances the mutation frequency for meropenem-selected car-
bapenem resistance in Pseudomonas aeruginosa, but use of the high-potency
drug doripenem inhibits mutant formation. Antimicrob. Agents Chemother. 52,
3795–3800. doi: 10.1128/AAC.00464-08
Tateda, K., Comte, R., Pechere, J. C., Kohler, T., Yamaguchi, K., and Van Delden,
C. (2001). Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother. 45, 1930–1933. doi: 10.1128/AAC.45.6.1930-
1933.2001
Wecke, T., and Mascher, T. (2011). Antibiotic research in the age of omics: from
expression proﬁles to interspecies communication. J. Antimicrob. Chemother. 66,
2689–2704. doi: 10.1093/jac/dkr373
Wolter, D. J., Schmidtke, A. J., Hanson, N. D., and Lister, P. D. (2007).
Increased expression of ampC in Pseudomonas aeruginosa mutants selected
with ciproﬂoxacin. Antimicrob. Agents Chemother. 51, 2997–3000. doi:
10.1128/AAC.00111-07
Yan, A., Guan, Z., and Raetz, C. R. (2007). An undecaprenyl
phosphate-aminoarabinose ﬂippase required for polymyxin resistance in
Escherichia coli. J. Biol. Chem. 282, 36077–36089. doi: 10.1074/jbc.M7061
72200
Yao, J. D. C., and Moellering, J. R. (2011). “Antibacterial Agents,” in Manual of
ClinicalMicrobiology, 10th Edn,Vol. 1, ed. J. Versalovic (Washington: ASM Press),
1043–1081.
Zhang, L., Dhillon, P., Yan, H., Farmer, S., and Hancock, R. E. (2000). Interactions
of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes
of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3317–3321. doi:
10.1128/AAC.44.12.3317-3321.2000
www.frontiersin.org January 2014 | Volume 4 | Article 422 | 7
“fmicb-04-00422” — 2014/1/6 — 20:15 — page 8 — #8
Morita et al. Low-dose antimicrobials against Pseudomonas aeruginosa
Zhu, L., Lin, J., Ma, J., Cronan, J. E., and Wang, H. (2010). Triclosan resistance
of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-
acyl carrier protein reductase. Antimicrob. Agents Chemother. 54, 689–698. doi:
10.1128/AAC.01152-09
Conflict of Interest Statement: The authors declare that the researchwas conducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 15 November 2013; accepted: 24 December 2013; published online: 08
January 2014.
Citation: Morita Y, Tomida J and Kawamura Y (2014) Responses of Pseudomonas
aeruginosa to antimicrobials. Front. Microbiol. 4:422. doi: 10.3389/fmicb.2013.00422
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section
of the journal Frontiers in Microbiology.
Copyright © 2014 Morita, Tomida and Kawamura. This is an open-access arti-
cle distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original pub-
lication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy January 2014 | Volume 4 | Article 422 | 8
